BioCryst Pharmaceuticals
BCRX
BCRX
270 hedge funds and large institutions have $1.63B invested in BioCryst Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 48 funds opening new positions, 91 increasing their positions, 100 reducing their positions, and 57 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more ownership
Funds ownership: →
9% less repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 100
6% less funds holding
Funds holding: 286 → 270 (-16)
16% less first-time investments, than exits
New positions opened: 48 | Existing positions closed: 57
Holders
270
Holding in Top 10
2
Calls
$12M
Puts
$7.76M
Top Buyers
| 1 | +$114M | |
| 2 | +$52.9M | |
| 3 | +$22.9M | |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$20.4M |
| 5 |
VPC
Vestal Point Capital
New York
|
+$16.3M |
Top Sellers
| 1 | -$41.5M | |
| 2 | -$37.3M | |
| 3 | -$27.5M | |
| 4 |
Morgan Stanley
New York
|
-$25M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$19.8M |
